Search results
Showing 76 to 87 of 87 results for hepatitis c
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
Developing NICE guidelines: the manual
New drugs 'a major benefit' for patients with chronic hepatitis C
NICE has recommended the use of boceprevir (Victrelis) and telaprevir (Incivo), both in combination with peginterferon alfa and ribavirin, as options for the treatment of the most common strain of hepatitis C in adults, in latest guidance.
NICE approves treatment for hep C in its 300th technology appraisal
NICE has recommended the use of peginterferon alfa in combination with ribavirin to treat chronic hepatitis C in children and young people, in its 300th piece of technology appraisal guidance.
Another ‘potential curative’ drug for people with chronic hepatitis C will be made available on the NHS.
As NICE publishes its 300th technology appraisal, we look back at the impact they have had on patient care.